Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
The European Medicines Agency (EMA) held a public hearing last year on the potentially permanent side effects of quinolone antibiotics. The resulting report from the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) incorporates the views of patients, health-care professionals and academics, including our group (see go.nature.com/2gextrj). Its recommendations, such as restricting the use of these drugs, have been adopted by the EMA’s Committee for Medicinal Products for Human Use, and will be ratified by the European Commission next month.